This test enables doctors to diagnose the condition earlier and less invasively, and to begin personalized treatment. This may include active pharmaceutical or surgical management.

HerResolve has demonstrated exceptional performance in validation studies and is intended to assist healthcare providers in diagnosing endometriosis as part of a comprehensive diagnostic approach. This approach may also include clinical evaluation, imaging (e.g., MRI, ultrasound), and/or laparoscopic surgery +/- histology.

Eligibility for HerResolve Testing

· Females AFAB (assigned female at birth)

· Ages 18 to 49 years old

· Experiencing any signs and/or symptom(s) suspicious of endometriosis (e.g. unexplained infertility, pelvic pain/chronic pelvic pain, abnormal bleeding, severely painful periods)

Exclusion Criteria for HerResolve Testing

· Pregnant or lactating

· Miscarriage in past 4 weeks

· Knowingly has cancer

· Undergoing cancer treatment

· Has received antibiotics within 1 week prior to testing.
A minimum 1-week washout period is required

· Has received GnRH, ovarian stimulation, IVF adjunctive,
and/or hormonal therapies within 4 weeks prior to
testing. A minimum 4-week washout period is required.
Oral contraceptives are excluded from this restriction

· Post-menopausal (≥ 1 year with no period)

HerResolve can only be ordered by healthcare providers and is currently available at clinics nationwide.

Robust supportive evidence for HerResolve includes a peer-reviewed clinical validation study published in the Journal of Minimally Invasive Gynecology (JMIG). This study evaluated hundreds of patients in collaboration with clinical sites across the U.S., Europe, and Hong Kong.